ancorabiotech

About ancorabiotech

This author has not yet filled in any details.
So far ancorabiotech has created 7 blog entries.

TNB-738, a biparatopic antibody, boosts intracellular NAD+ by inhibiting CD38 ecto-enzyme activity

ABSTRACT  Cluster of differentiation 38 (CD38) is an ecto-enzyme expressed primarily on immune cells that metabolize nicotinamide adenine dinucleotide (NAD+) to adenosine diphosphate ribose or cyclic ADP-ribose and nicotinamide. Other substrates of CD38 include nicotinamide adenine dinucleotide phosphate and nicotinamide mononucleotide, a critical NAD+ precursor in the salvage pathway. NAD+ is an important coenzyme

By |2022-08-04T16:01:12+00:00August 1st, 2022|News|Comments Off on TNB-738, a biparatopic antibody, boosts intracellular NAD+ by inhibiting CD38 ecto-enzyme activity

How Venture Capitalists Made Bet on Drugmaker Teneobio Pay Off

Investment in the startup has led to a series of profitable deals, including one with AstraZeneca worthnearly $1.27 billion. Venture-capital backers of Teneobio Inc. have parlayed their bet on the biotechnology startup into a series of acquisition deals, illustrating the creativity some investors are using to wring profits from the sector.  Typically, venture capitalists

By |2022-08-04T15:56:12+00:00July 22nd, 2022|News|Comments Off on How Venture Capitalists Made Bet on Drugmaker Teneobio Pay Off

Ancora Biotech: TeneoTwo Acquisition & What’s Next

Original Article By Galym Imanbayev and Jonathan MacQuitty - on Medium Today, AstraZeneca announced its agreement to acquire TeneoTwo, a subsidiary of TBio which is managed by Ancora Biotech, for $100M upfront as part of a total transaction value of $1.265B including milestones. The acquisition will accelerate the development of TeneoTwo’s CD19/CD3 T-cell engager for

By |2022-07-08T18:40:20+00:00July 7th, 2022|News|Comments Off on Ancora Biotech: TeneoTwo Acquisition & What’s Next

AstraZeneca to acquire TeneoTwo and its clinical-stage T-cell engager, strengthening haematological cancer pipeline

TNB-486 will be evaluated in multiple types of lymphoma AstraZeneca today announced an agreement to acquire TeneoTwo, Inc. (TeneoTwo)i, including its Phase I clinical-stage CD19/CD3 T-cell engager, TNB-486, currently under evaluation in relapsed and refractory B-cell non-Hodgkin lymphoma1. The acquisition of TNB-486 aims to accelerate the development of this potential new medicine for B-cell haematologic

By |2022-07-08T18:36:47+00:00July 5th, 2022|News|Comments Off on AstraZeneca to acquire TeneoTwo and its clinical-stage T-cell engager, strengthening haematological cancer pipeline

Exclusive: After Amgen exit, father-son duo gets Lightspeed backing to fund remaining Teneobio ‘babies’

By Kyle LaHucik, Endpoints The father-son duo behind Teneobio is back with another biotech, comprising three bispecific antibodies that neither Amgen wanted when dishing out $900 million upfront last year, nor AbbVie wanted when acquiring a multiple myeloma asset in 2019. Technically, Ancora Biotech is three shell companies, one for each of its antibodies

By |2022-07-08T18:37:00+00:00June 18th, 2022|News|Comments Off on Exclusive: After Amgen exit, father-son duo gets Lightspeed backing to fund remaining Teneobio ‘babies’

June 9 Quick Takes: Venturerounds for Tessa, Degron, Ancora,Charm and Relation

A new $126 million series A round will recapitalize Singapore-based Tessa Therapeutics Ltd. as it advances a pipeline ofcell therapies, including one headed into a pivotal study.Polaris Partners led the round alongside prior investorsTemasek, EDBI, Heliconia Capital and Heritas Capital. Thebiotech had raised at least $130 million during 2017-18, buthas shifted focus to its current

By |2022-07-08T18:37:21+00:00June 9th, 2022|News|Comments Off on June 9 Quick Takes: Venturerounds for Tessa, Degron, Ancora,Charm and Relation

Newly-Formed Ancora Biotech

Newly-Formed Ancora Biotech Will Continue Operations of Teneobio Spin-offs After Successful Acquisition of Teneobio by Amgen NEWARK, Calif., October 26, 2021 - Ancora Biotech announced, in connection with the closing of the acquisition of Teneobio, Inc., by Amgen Inc., that Teneobio’s former shareholders and their representatives will provide oversight of three previous affiliates of

By |2022-07-08T18:37:34+00:00October 26th, 2021|News|Comments Off on Newly-Formed Ancora Biotech
Go to Top